Artículos por temáticas

Combination Supplement Therapy: A New Frontier in Treatment of Neurodegenerative Diseases

Shtilbans A.

J Nutr. 2025 Jul 15:S0022-3166(25)00427-4. doi: 10.1016/j.tjnut.2025.07.004. Online ahead of print.

A multicenter longitudinal study of cholinergic subgroups in Parkinson disease

Bohnen NI, Roytman S, van der Zee S, Carli G, Michalakis F, Luker A, Slingerland S, Frey KA, Scott PJH, Koeppe RA, van Laar T, Albin RL, Kanel P.

Nat Commun. 2025 Jul 1;16(1):5655. doi: 10.1038/s41467-025-60815-0.

Acupuncture for the anxiety and depression in Parkinson disease: A systematic review and network meta-analysis

Zhou H, Zhong H, Ying W, Li Z, Nie Y, Zhang B.

Medicine (Baltimore). 2025 Aug 8;104(32):e42136. doi: 10.1097/MD.0000000000042136.

Comment on "Epidemiology, clinical characteristics and life-threatening risk profile of WPW in children: a single-center experience in South Wales for 30 years"

Ali M, Khan AA, Syed R, Noor M, Ullah H.

Eur J Pediatr. 2025 Aug 16;184(9):557. doi: 10.1007/s00431-025-06414-z.

Effect of group exercise on quality of life for Parkinson disease: systematic review and meta-analysis

Palm D, Swarowsky A, Kelly M, Grugel S, Stiers C, Wolden M.

Disabil Rehabil. 2025 Aug;47(17):4366-4378. doi: 10.1080/09638288.2025.2453636. Epub 2025 Jan 26.

Novel SPR mutation in first Chinese patient with sepiapterin reductase deficiency: urinary biomarker validation in oldest treated case

Zheng X, Ying C, Xie F, Cen Z, Luo W.

Neurol Sci. 2025 Aug;46(8):4011-4015. doi: 10.1007/s10072-025-08219-2. Epub 2025 May 1.

A diagnostic challenge: spinocerebellar ataxia type 6 presenting with dystonia and parkinsonism

Koren TJ, Ahmad KE, Kumar KR, Lubomski M.

BMJ Case Rep. 2025 Aug 22;18(8):e266791. doi: 10.1136/bcr-2025-266791.

Parkinson Disease

Rawls A, Okun MS.

Continuum (Minneap Minn). 2025 Aug;31(4):930-955. doi: 10.1212/cont.0000000000001593. Epub 2025 Aug 1.

Use of safinamide for treatment of Parkinson disease: real-world data from Spain

Morales Casado MI, López Ariztegui N.

Drugs Context. 2025 Jul 25;14:2025-5-5. doi: 10.7573/dic.2025-5-5. eCollection 2025.

Comparison and cutoff values of two amyloid PET scaling methods: centiloid scale and amyloid-β load

Yamakuni R, Abe M, Ukon N, Matsuda H, Takano H, Sawamoto N, Shima A, Mori Y, Sekino H, Ishii S, Fukushima K, Mizuno T, Narumoto J, Hanakawa T, Ito H; Parkinson’s and Alzheimer’s disease Dimensional Ne

Ann Nucl Med. 2025 Aug;39(8):799-812. doi: 10.1007/s12149-025-02051-6. Epub 2025 Apr 26.

The basics of PET molecular imaging in neurodegenerative disorders with dementia and/or parkinsonism

Bronte A, Prieto E, Quincoces G, Erro E, Arbizu J.

Eur Radiol. 2025 Aug;35(8):4621-4634. doi: 10.1007/s00330-025-11388-5. Epub 2025 Feb 6.

Lehigh Valley Procedure: Combined Pulmonary Vein Isolation and Accessory Pathway Ablation for Atrial Fibrillation in Wolff-Parkinson-White Syndrome

Sabri MS, Benedict L, Souder D, Kaugars L, Patel K, Bozorgnia B, Nazir T.

Methodist Debakey Cardiovasc J. 2025 Aug 20;21(1):74-80. doi: 10.14797/mdcvj.1618. eCollection 2025.

Correcting SUVR bias by accounting for radiotracer clearance in tissue: A validation study with [(18)F]FE-PE2I PET in cross-sectional, test-retest and longitudinal cohorts

Oh M, Honhar P, Carson RE, Hillmer AT, Varrone A.

J Cereb Blood Flow Metab. 2025 Jul;45(7):1357-1370. doi: 10.1177/0271678X251322407. Epub 2025 Feb 21.

The Gut-Brain Axis in Parkinson disease: Emerging Concepts and Therapeutic Implications

Menozzi E, Schapira AHV, Borghammer P.

Mov Disord Clin Pract. 2025 Jul;12(7):904-916. doi: 10.1002/mdc3.70029. Epub 2025 Mar 13.

The tongue muscles: Clinical applications in lingual dystonia

Rosales RL, Endaya NJ.

Toxicon. 2025 Jul;262:108382. doi: 10.1016/j.toxicon.2025.108382. Epub 2025 May 9.